NCT02094729: A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
- State
- Completed
- Phase
- Phase 1
- People
- 26 taking part
- Started
- Sep 2013
- Primary completion
- Mar 2015
- Arms
- BAN2401 2.5 mg/kg, BAN2401 5 mg/kg, BAN2401 10 mg/kg
- Results
- None posted
- 24 Mar 2014: Trial registered